- The acquisition will deliver strong commercial synergy with Hasten’s current critical care portfolio
Shanghai, May 4th , 2023 – Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired
Under the agreement, Hasten acquire
“Hasten is committed to building a leading innovative medical and healthcare enterprise in China. The acquisition of Rocephin® delivers strong commercial synergy with Hasten’s current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments, and positions us well to continue providing best-in-class treatments to benefit more patients,” Summer Xia, CEO of Hasten Biopharma, said.
Hasten is an investment of CBC Group, Asia's largest healthcare-dedicated investment firm headquartered in Singapore, Hefei Industry Investment Group, and Feidong County of Hefei City.